Target intelligence / Profile preview

L-serine (Ser) (Ser)

Target
Ser
Molecular classification
Amino acid, Metabolite, Endogenous signaling molecule
01

Overview

Serine is a non-essential amino acid that exists in two enantiomers, L-serine and D-serine, both of which are critical for human physiology. L-serine serves as a fundamental building block for protein synthesis and a precursor for essential metabolites, including glycine, cysteine, and sphingolipids (PubChem CID 5951). D-serine, synthesized from L-serine by the enzyme serine racemase, acts as an obligatory co-agonist at the glycine-binding site of the N-methyl-D-aspartate (NMDA) receptor, playing a vital role in excitatory neurotransmission, synaptic plasticity, and memory (NIH/NCBI). While serine itself is a metabolite and not a classical therapeutic protein target like an enzyme or receptor, its metabolic pathways are highly relevant in medicine. L-serine supplementation is currently being investigated as a therapy for neurodegenerative conditions such as Amyotrophic Lateral Sclerosis (ALS) and Hereditary Sensory and Autonomic Neuropathy type 1 (HSAN1), where it may mitigate the production of neurotoxic deoxysphingolipids (PubMed). Furthermore, the upregulation of serine biosynthesis is a hallmark of certain cancers, which rely on the pathway to support rapid cellular proliferation, making the enzymes involved in its synthesis potential targets for oncology (Nature Reviews Cancer).

Other names
(2S)-2-amino-3-hydroxypropanoic acidL-Ser2-amino-3-hydroxypropionic acidS-serine
02

Mechanism of action

As a metabolite, L-serine acts as a substrate for protein and lipid synthesis; the D-enantiomer acts as a mandatory co-agonist for the NMDA receptor glycine site.

03

Biological functions

Protein biosynthesisNeuromodulation (via D-serine co-agonism of NMDA receptors)Sphingolipid synthesisOne-carbon metabolism (precursor for glycine and cysteine)Nucleotide synthesis
04

Disease associations

Amyotrophic lateral sclerosis (ALS)Hereditary sensory and autonomic neuropathy type 1 (HSAN1)Schizophrenia (associated with D-serine deficiency)Cancer (metabolic reprogramming)Neurological disorders
05

Safety considerations

Potential neurotoxicity at excessively high concentrations of D-serineMetabolic interference with other neutral amino acids via competitive transport across the blood-brain barrierRenal toxicity observed in high-dose animal studies
06

Interacting drugs

L-serine (Investigational)

3 more in the full profile.

07

Biomarkers

Plasma L-serine concentrationCerebrospinal fluid (CSF) D-serine levelsSerine-to-glycine ratioPHGDH expression levels (in cancer context)

Beyond the preview

Go deeper on L-serine (Ser) (Ser).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-serine (Ser) (Ser).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call